Improvement in postburn hypertrophic scar after treatment with IFN-α2b is associated with decreased fibrocytes

Journal of Interferon and Cytokine Research

Volumn 27, Issue 11, 2007, Pages 921-930

  Wang, Jianfei ^a   Jiao, Haiyan ^a   Stewart, Tara L ^a   Shankowsky, Heather A ^a   Scott, Paul G ^a   Tredget, Edward E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BIOLOGICAL MARKER; CD34 ANTIGEN; CD45 ANTIGEN; LEUKOCYTE SPECIFIC PROTEIN 1; PROCOLLAGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BURN; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROBLAST; FIBROCYTE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MONONUCLEAR CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN FIBROSIS; TREATMENT RESPONSE; WOUND HEALING;

ACTINS; ADOLESCENT; ADULT; BURNS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CICATRIX, HYPERTROPHIC; FEMALE; HUMANS; INTERFERON ALFA-2B; LEUKOCYTES; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PROCOLLAGEN; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 36849036828     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0008     Document Type: Article

References (39)

1. Scott PG, Ghahary A, Tredget EE. Molecular and cellular aspects of fibrosis following thermal injury. Hand Clin. 2000;16:271-287.
2. Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures. The cellular and molecular basis for therapy. Surg. Clin. North Am. 1997;77:701-730.
3. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994;1:71-81.
4. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 2004;36:598-606.
5. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell. Mol. Life Sci. 2003;60:1342-1350.
6. Yang L, Scott PG, Giuffre J, Shankowsky HA, Ghahary A, Tredget EE. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab. Invest. 2002;82:1183-1192.
7. Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA, Ghahary A, Tredget EE. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen. 2005;13:398-404.
8. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 2001;166:7556-7562.
9. Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 2001;15:2215-2224.
10. Mori L, Bellini A, Stacey MA, Schmidt M, Mattoli S. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp. Cell. Res. 2005;304:81-90.
11. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004;114:438-446.
12. Hashimoto N, Jin H, Liu T, Chensue SW, Phan SH. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 2004;113:243-252.
13. Chesney J, Metz C, Stavitsky AB, Bacher M, Bucala R. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 1998;160:419-425.
14. Wang JF, Jiao H, Stewart TL, Shankowsky HA, Scott PG, Tredget EE. Fibrocytes from burn patients regulate the activities of fibroblasts. Wound Repair Regen. 2007;15:113-121.
15. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol. 2002;71:565-581.
16. Lasky JA, Ortiz LA. Antifibrotic therapy for the treatment of pulmonary fibrosis. Am. J. Med. Sci. 2001;322:213-221.
17. Pestka S, Meager A. Interferon standardization and designations. J. Interferon Cytokine Res. 1997;17(Suppl 1):S9-14.
18. Inagaki Y, Nemoto T, Kushida M, Sheng Y, Higashi K, Ikeda K, Kawada N, Shirasaki F, Takehara K, Sugiyama K, Fujii M, Yamauchi H, Nakao A, de Crombrugghe B, Watanabe T, Okazaki I. Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 2003;38:890-899.
19. Larrabee WF Jr., East CA, Jaffe HS, Stephenson C, Peterson KE. Intralesional interferon gamma treatment for keloids and hypertrophic scars. Arch. Otolaryngol. Head Neck Surg. 1990;116:1159-1162.
20. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP. A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings. Arch. Dermatol. 1990;126:1295-1302.
21. Sanders JL, Dodd C, Ghahary A, Scott PG, Tredget EE: The effect of interferon-alpha2b on an in vitro model Dupuytren's contracture. J. Hand Surg. [Am] 1999;24:578-585.
22. Loquai C, Nashan D, Metze D, Beiteke U, Ruping KW, Luger TA, Grabbe S. Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases. Hautarzt 2004;55:176-181.
23. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1999;341:1264-1269.
24. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, Iwashina T, Ghahary A, Taerum TV, Scott PG. Transforming growth factorbeta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast. Reconstr. Surg. 1998;102:1317-1328.
25. Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A. Transforming growth factor-β mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-α and IFN-γ in vitro and in vivo. J. Interferon Cytokine Res. 2000;20:143-151.
26. Nedelec B, Shankowsky H, Scott PG, Ghahary A, Tredget EE. Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b. Surgery 2001;130:798-808.
27. Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. Rating the burn scar. J. Burn Care Rehabil. 1990;11:256-260.
28. Schmidt M, Sun G, Stacey MA, Mori L, Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 2003;171:380-389.
29. Scott PG, Ghahary A, Tredget EE. Biological basis of hypertrophic scarring. Adv. Struct. Biol. 1994;3:157-201.
30. Daubener W, MacKenzie CR. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 1999;467:517-524.
31. Sarkhosh K, Tredget EE, Li Y, Kilani RT, Uludag H, Ghahary A. Proliferation of peripheral blood mononuclear cells is suppressed by the indoleamine 2,3-dioxygenase expression of interferon-gamma-treated skin cells in a co-culture system. Wound Repair Regen. 2003;11:337-345.
32. Harrop AR, Ghahary A, Scott PG, Forsyth N, Uji-Friedland A, Tredget EE. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scar fibroblasts in vitro by interferon-gamma. J. Surg. Res. 1995;58:471-477.
33. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-beta1 mRNA and protein than normal skin and cells. Wound Repair Regen. 2000;8:128-137.
34. Nedelec B, Shen YJ, Ghahary A, Scott PG, Tredget EE. The effect of interferon alpha 2b on the expression of cytoskeletal proteins in an in vitro model of wound contraction. J. Lab. Clin. Med. 1995;126:474-484.
35. Nedelec B, Dodd CM, Scott PG, Ghahary A, Tredget EE. Effect of interferon-alpha2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo. Wound Repair Regen. 1998;6:202-212.
36. Tredget EE, Yang L, Delehanty M, Shankowsky H, Scott PG. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J. Interferon Cytokine Res. 2006;26:179-189.
37. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 1996;17:369-372.
38. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc. Natl. Acad. Sci. USA 1994;91:1198-1205.
39. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-1021.